GlassScriptPhysician profile
Melissa Alvarez
NPI 1912497280
$2,800.18
in general payments reported to CMS, 2019-2025
21 companies · $1,428 in 2025
The $1,428 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $346 · 2021: $244 · 2022: $99.99 · 2023: $429 · 2024: $253 · 2025: $1,428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,632 · Travel and Lodging: $317 · Education: $161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,631.68 |
| Travel and Lodging | $317.18 |
| Education | $161.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $631.01 | 2025 | General - Therapies, Versacross Access Solution |
| Abiomed | $230.56 | 2024-2025 | Impella |
| Medtronic, INC. | $219.34 | 2023-2024 | Onyx Frontier, Micra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.08 | 2023-2025 | Jardiance |
| Amgen INC. | $187.76 | 2021-2025 | Repatha |
| Abbott Laboratories | $169.59 | 2025 | Diamondback Coronary |
| Astellas Pharma US INC | $139.09 | 2022-2023 | Lexiscan |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2023 | Camzyos |
| Alexion Pharmaceuticals, INC. | $124.99 | 2021 | |
| Allergan, INC. | $121.74 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $119.58 | 2023-2025 | Wainua |
| Abbvie INC. | $116.21 | 2020 | |
| Novo Nordisk INC | $107.77 | 2020 | |
| Teleflex LLC | $105.80 | 2025 | Turnpike |
| Actelion Pharmaceuticals US, INC. | $77.45 | 2025 | Uptravi, Opsumit |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $31.25 | 2025 | |
| Bridgebio Pharma, INC. | $25.14 | 2025 | Attruby |
| Janssen Biotech, INC. | $21.42 | 2025 | Darzalex, Talvey, Tecvayli |
| Alnylam Pharmaceuticals INC. | $17.81 | 2025 | Amvuttra |
| Pfizer INC. | $16.25 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.34 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Alvarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.